Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to 19347.92%.

  • Perspective Therapeutics' EBITDA Margin fell 131365800.0% to 19347.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 14200.48%, marking a year-over-year decrease of 157144900.0%. This contributed to the annual value of 6464.15% for FY2024, which is 36091300.0% down from last year.
  • Per Perspective Therapeutics' latest filing, its EBITDA Margin stood at 19347.92% for Q3 2025, which was down 131365800.0% from 14057.89% recorded in Q2 2025.
  • In the past 5 years, Perspective Therapeutics' EBITDA Margin registered a high of 238.19% during Q4 2023, and its lowest value of 19347.92% during Q3 2025.
  • Its 5-year average for EBITDA Margin is 4075.13%, with a median of 456.68% in 2023.
  • As far as peak fluctuations go, Perspective Therapeutics' EBITDA Margin soared by 1018400bps in 2021, and later crashed by -148909600bps in 2024.
  • Over the past 5 years, Perspective Therapeutics' EBITDA Margin (Quarter) stood at 58.06% in 2021, then crashed by -322bps to 245.08% in 2022, then surged by 197bps to 238.19% in 2023, then crashed by -6252bps to 14652.77% in 2024, then crashed by -32bps to 19347.92% in 2025.
  • Its EBITDA Margin was 19347.92% in Q3 2025, compared to 14057.89% in Q2 2025 and 10201.87% in Q1 2025.